Medivation and Astellas Pharma announced that the companies have established an updated interim analysis plan for the PREVAIL trial, a global Phase 3 clinical trial evaluating xtandi capsules in men with metastatic castration-resistant prostate cancer, or mCRPC, who have not yet received chemotherapy. The planned interim analysis for the PREVAIL trial is expected to occur in 2013. In addition, the protocol-specified number of radiographic progression-free survival, or PFS, events has been exceeded, and the primary PFS analysis will occur at the time of the interim analysis for overall survival. Medivation is conducting this study under its agreement with Astellas.
- Pharmaceuticals & Drug Trials
- Astellas Pharma